Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · January 31, 2022

Cutaneous Immune-Related Adverse Events Are Associated With Increased Survival in Patients Treated With Anti-PD-1 and Anti-PD-L1 Therapy

JAMA Dermatology


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Dermatology
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy
JAMA Dermatol 2022 Jan 12;[EPub Ahead of Print], K Tang, J Seo, BC Tiu, TK Le, V Pahalyants, NS Raval, PO Ugwu-Dike, L Zubiri, V Naranbhai, M Carrington, A Gusev, KL Reynolds, NR LeBoeuf, MM Asgari, SG Kwatra, YR Semenov

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading